Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - hydroxyzine dihydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. as a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. oral hydroxyzine hydrochloride

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

remedyrepack inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii 1 as follows: generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: - motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. - autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. - apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. - vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. the above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. however, mild depressive symptoms are common in gad. the effectiveness of buspirone hydrochloride tablets in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. there is no body of evidence available that systematically addresses the appropriate duration of treatment for gad. however, in a study of long-term use, 264 patients were treated with buspirone hydrochloride tablets for 1 year without ill effect. therefore, the physician who elects to use buspirone hydrochloride tablets for extended periods should periodically reassess the usefulness of the drug for the individual patient. buspirone hydrochloride tablets are contraindicated in patients hypersensitive to buspirone hydrochloride. the use of monoamine oxidase inhibitors (maois) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. the use of buspirone within 14 days of stopping an maoi intended to treat depression is also contraindicated. starting buspirone in a patient who is being treated with reversible maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see warnings , dosage and administration and drug interactions ). buspirone hydrochloride is not a controlled substance. in human and animal studies, buspirone has shown no potential for abuse or diversion and there is no evidence that it causes tolerance, or either physical or psychological dependence. human volunteers with a history of recreational drug or alcohol usage were studied in two double-blind clinical investigations. none of the subjects were able to distinguish between buspirone hydrochloride tablets and placebo. by contrast, subjects showed a statistically significant preference for methaqualone and diazepam. studies in monkeys, mice, and rats have indicated that buspirone lacks potential for abuse. following chronic administration in the rat, abrupt withdrawal of buspirone did not result in the loss of body weight commonly observed with substances that cause physical dependency. although there is no direct evidence that buspirone hydrochloride tablets cause physical dependence or drug-seeking behavior, it is difficult to predict from experiments the extent to which a cns-active drug will be misused, diverted, and/or abused once marketed. consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely, observing them for signs of buspirone hydrochloride tablets misuse or abuse (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - hydroxyzine dihydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. as a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. hydroxyzine is contraindicated in patients with a prolonged qt interval. hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. clinical data in human beings are inadequate to establish safety in early pregnancy. until such data are available, hydroxyzine is contraindicated in early pregnancy. hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - hydroxyzine dihydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. as a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. hydroxyzine is contraindicated in patients with a prolonged qt interval. hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. clinical data in human beings are inadequate to establish safety in early pregnancy. until such data are available, hydroxyzine is contraindicated in early pregnancy. hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - hydroxyzine dihydrochloride (unii: 76755771u3) (hydroxyzine - unii:30s50ym8og) - for symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses and in histamine-mediated pruritus. as a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. atropine and other belladonna alkaloids are not affected by the drug. hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. the effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. the physician should reassess periodically the usefulness of the drug for the individual patient. oral hydroxyzine hydrochloride is contraindicated in patients with known hypersensitivity to hydroxyzine hydrochloride products, and in patients with known hypersensitivity to cetirizine hydrochloride or levocetirizine hydrochloride. hydroxyzine is contraindicated in patients with a prolonged qt interval. hydroxyzine, when administered to the pregnant mouse, rat, and rabbit induced fetal abnormalities in the rat and mouse at doses substantially above the human therapeutic range. clinical data in human beings are inadequate to establish safety in early pregnancy. until such data are available, hydroxyzine is contraindicated in early pregnancy. hydroxyzine is contraindicated for patients who have shown a previous hypersensitivity to any component of this medication.

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

bryant ranch prepack - vardenafil hydrochloride (unii: 5m8s2cu0ts) (vardenafil - unii:uce6f4125h) - vardenafil hydrochloride tablets are indicated for the treatment of erectile dysfunction. administration of vardenafil hydrochloride tablets with nitrates (either regularly and/or intermittently) and nitric oxide donors is contraindicated [see clinical pharmacology (12.2)] . consistent with the effects of pde5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, pde5 inhibitors, including vardenafil hydrochloride tablets, may potentiate the hypotensive effects of nitrates. a suitable time interval following dosing of vardenafil hydrochloride tablets for the safe administration of nitrates or nitric oxide donors has not been determined. do not use vardenafil hydrochloride tablets in patients who are using a gc stimulator, such as riociguat. pde5 inhibitors, including vardenafil hydrochloride tablets may potentiate the hypotensive effects of gc stimulators. risk summary vardenafil hydrochloride is not indicated for use in females. there are no data with the use of vardenafil hydrochloride in pregnant women to inform any drug-associated risks. in animal reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafil during organogenesis at exposures for unbound vardenafil and its major metabolite at approximately 100 and 29 times, respectively, the maximum recommended human dose (mrhd) of 20 mg based on auc (see data) . data animal data no evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis. this dose is approximately 100 fold (rat) and 29 fold (rabbit) greater than the auc values for unbound vardenafil and its major metabolite in humans given the mrhd of 20 mg. in the rat pre- and postnatal development study, the noael (no observed adverse effect level) for maternal toxicity was 8 mg/kg/day. retarded physical development of pups in the absence of maternal effects was observed following maternal exposure to 1 and 8 mg/kg possibly due to vasodilatation and/or secretion of the drug into milk. the number of living pups born to rats exposed pre- and postnatally was reduced at 60 mg/kg/day. based on the results of the pre- and postnatal study, the developmental noael is less than 1 mg/kg/day. based on plasma exposures in the rat developmental toxicity study, 1 mg/kg/day in the pregnant rat is estimated to produce total auc values for unbound vardenafil and its major metabolite comparable to the human auc at the mrhd of 20 mg. risk summary vardenafil hydrochloride is not indicated for use in females. there is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. vardenafil is present in rat milk of lactating rats (see data) . data vardenafil was secreted into the milk of lactating rats at concentrations approximately 10-fold greater than found in the plasma. following a single oral dose of 3 mg/kg, 3.3% of the administered dose was excreted into the milk within 24 hours. vardenafil hydrochloride is not indicated for use in pediatric patients. safety and efficacy have not been established in this population. elderly males 65 years of age and older have higher vardenafil plasma concentrations than younger males (18 to 45 years), mean cmax and auc were 34% and 52% higher, respectively. phase 3 clinical trials included more than 834 elderly patients, and no differences in safety or effectiveness of vardenafil 5, 10, or 20 mg were noted when these elderly patients were compared to younger patients. however, due to increased vardenafil concentrations in the elderly, a starting dose of 5 mg vardenafil should be considered in patients ≥65 years of age [see clinical pharmacology (12.3)] . dosage adjustment is necessary in patients with moderate hepatic impairment. do not use vardenafil hydrochloride in patients with severe hepatic impairment (child-pugh c). vardenafil has not been evaluated in this patient population. a starting dose of 5 mg is recommended in patients with moderate hepatic impairment (child-pugh b) and the maximum dose should not exceed 10 mg. in volunteers with moderate hepatic impairment, the cmax and auc following a 10 mg vardenafil dose were increased by 130% and 160%, respectively, compared to healthy control subjects [see warnings and precautions (5.8) and dosage and administration (2.3)] . in volunteers with mild hepatic impairment (child-pugh a), the cmax and auc following a 10 mg vardenafil dose were increased by 22% and 17%, respectively, compared to healthy control subjects. no dosage adjustment is necessary in patients with mild hepatic impairment. do not use vardenafil hydrochloride in patients on renal dialysis as vardenafil has not been evaluated in such patients. no dosage adjustment is necessary in patients with creatinine clearance (clcr ) of 30 to 80 ml/min. in male volunteers with clcr = 50 to 80 ml/min, the pharmacokinetics of vardenafil were similar to those observed in a control group with clcr > 80 ml/min. in male volunteers with clcr = 30 to 50 ml/min or clcr < 30 ml/min, the auc of vardenafil was 20 to 30% higher compared to that observed in a control group with clcr > 80 ml/min [see dosage and administration (2.3) and warnings and precautions (5.9)] .

Statele Unite ale Americii - engleză - NLM (National Library of Medicine)

proficient rx lp - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du

Grecia - engleză - HMA (Heads of Medicines Agencies)

le vet b.v - benazepril hydrochloride 5 mg - tablet - dogs non food - benazepril

Ungaria - engleză - HMA (Heads of Medicines Agencies)

le vet b.v - benazepril hydrochloride 5 mg - tablet - dogs non food - benazepril

Țările de Jos - engleză - HMA (Heads of Medicines Agencies)

le vet b.v - benazepril hydrochloride 5 mg - tablet - dogs non food - benazepril